Rolf Wagner

USPTO Granted Patents = 48 (Patent Applications = 20)

CIPO Patents = 10 (Patent Applications = 14)

EPO Patents = 18 (Patent Applications = 35)

Average Co-Inventor Count = 8.1

ph-index = 11

Forward Citations = 452(Granted Patents)

Location History:

Libertyville, IL (US) (1996 - 1998)
Gurnee, IL (US) (1995 - 2012)
Antioch, IL (US) (2010 - 2018)

Company Filing History:

27 out of 4,177

Abbott Laboratories Corporation

Reata Pharmaceuticals, Inc.

patents

4. 2 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 1995-2018

Loading Chart...

48 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 10053474 - Anti-viral compounds (2018-08-21),

2. 10039754 - Anti-viral compounds (2018-08-07),

3. 10028937 - Anti-viral compounds (2018-07-24),

4. 9676797 - Anti-viral compounds (2017-06-13),

5. 9637478 - Antiviral compounds and uses thereof (2017-05-02),

6. 9586978 - Anti-viral compounds (2017-03-07),

7. 9464082 - Aryl and arylalkyl substituted pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators (2016-10-11),

8. 9353091 - Antiviral compounds and uses thereof (2016-05-31),

9. 9139536 - Anti-infective agents and uses thereof (2015-09-22),

10. 9095590 - Anti-infective agents and uses thereof (2015-08-04),

11. 9006387 - Anti-viral compounds (2015-04-14),

12. 8986740 - Anti-infective agents and uses thereof (2015-03-24),

13. 8937150 - Anti-viral compounds (2015-01-20),

14. 8921514 - Anti-viral compounds (2014-12-30),

15. 8748443 - Antiviral compounds and uses thereof (2014-06-10),

Title: Spotlight on Inventor Rolf Wagner

Introduction:

Rolf Wagner, a prolific inventor based in Antioch, IL, has made significant contributions to the field of antiviral compounds with a total of 48 patents under his name. His innovative work focuses on inhibiting the Hepatitis C virus (HCV) polymerase, showcasing his dedication to advancing medical solutions.

Latest Patents:

Among his latest patents, Rolf Wagner has introduced groundbreaking anti-viral compounds designed to combat and inhibit the Hepatitis C virus. These compounds not only target the replication of HCV but also include processes for their manufacturing, compositions incorporating these compounds, and methods for effectively treating HCV infections.

Career Highlights:

With an impressive track record, Rolf Wagner has previously lent his expertise to renowned companies such as Abbott Laboratories Corporation and AbbVie Inc. His tenure at these organizations speaks volumes about his knowledge and leadership in the pharmaceutical industry, particularly in the development of antiviral medications.

Collaborations:

Throughout his career, Rolf Wagner has collaborated with esteemed professionals in the field, including Todd Warren Rockway and Allan C. Krueger. These partnerships have further enriched his patent portfolio and fostered a culture of innovation and collective growth within the industry.

Conclusion:

In conclusion, Rolf Wagner stands as a prominent figure in the realm of antiviral research and development, exemplifying a steadfast commitment to pioneering solutions for combating infectious diseases like Hepatitis C. His work continues to inspire and drive advancements in the medical field, making him a respected inventor and innovator in his field.

This text is generated by artificial intelligence and may not be accurate.